Total Funding
34
1
Total FundingVenture - Series Unknown raised
Growth Score
-6 pts
Heat Score
-45 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
376139
ExIthera Pharmaceuticals supports the creation of antithrombotic and stroke prevention medications.
Acquired by 
Cadrenal Therapeutics
Neil J. Hayward: CEO
William Koster: Director (Chairman)
About the Company
ExIthera Pharmaceuticals is a developer of an early-stage biotechnology platform used to develop small-molecule pharmaceuticals. The company's stroke prevention and antithrombosis drugs are based on the unique pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. It focuses on
developing stroke prevention and anti-thrombosis drugs based on Factor XI, which has a pathophysiological role in the initiation of intravascular thrombi without causing undue bleeding, enabling physicians to treat serious consequences, including venous thromboembolism, deep vein thrombosis, stroke, and heart attack.
